Emicizumab is an antibody against Factor IXa and Factor X used to treat hemophilia A. Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.
- Mechanism
- Curator reviewed · 2 references
Emicizumab exerts its action by performing the function of the coagulation Factor VIII without presenting a structural homology. It presents a dual specificity which allows it to bind to both the Factor IXa and Factor X, performing the required bridging activity for the launch of the coagulation cascade.
- Primary indication
- The main function of Emicizumab is the prevention of bleeding episodes.Curator reviewed · 2 structured indications
- Formula / weight
- C6434-H9940-N1724-O2047-S45 · 145637.0 Da
- First approval
- Canada, 2018 · United States, 2017 · European Union, 2020
- Also known as
- emicizumab-kxwh
- Code names
- ACE-910 · RG6013 · RO5534262
- Brand names
Resolves to
What you can answer from here — as of May 14, 2026
Which drugs share a target with Emicizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account